Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/SEAGEN-INC-10808/news/Seattle-Genetics-Initiates-Phase-1-2-Clinical-Trial-of-SGN-CD33A-Vadastuximab-Talirine-Before-or-21452356/?utm_source=whatsapp&utm_medium=social&utm_campaign=share